Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

Phase 3 Completed 200 enrolled GlaxoSmithKline

RandomizedParallel-groupQuadruple-blindPrevention

The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children

Evaluation	Drug	Modality	Dose	Route
Subject	257049	Vaccine	0.5 ml	Intramuscular
Comparator	Human Diploid Cell Vaccine	Vaccine	0.5 ml	Intramuscular
Comparator	Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).	Vaccine	0.5 ml	Intramuscular
Comparator	Purified Verocell Rabies Vaccine	Vaccine	0.5 ml	Intramuscular